Abbreviations & Acronyms ABCB1 = adenosine triphosphatebinding cassette subfamily B member 1 ABCC2 = adenosine triphosphatebinding cassette subfamily C member 2 ABCG2 = adenosine triphosphatebinding cassette subfamily G member 2 AE = adverse event AUC = area under the curve AUC sum = total area under the curve of temsirolimus and sirolimus AUC TOT = area under the curve from time zero to infinity BP = blood pressure C 0 = trough concentration C max = maximum concentration C ss = steady state concentration CYP = cytochrome P450 FKBP12 = FK-506 binding protein-12 HCC = hepatocellular carcinoma HFS = hand-foot syndrome HT = hypertension mTOR = mammalian target of rapamycin mTORC1 = mammalian target of rapamycin complex 1 NR1I2 = nuclear receptor subfamily 1 group I member 2 OS = overall survival PD = pharmacodynamics PFS = progression-free survival PK = pharmacokinetics PM = poor metabolizer PR = partial response RCC = renal cell carcinoma RR = risk ratio SNP = single nucleotide polymorphism T 1/2 = half-life time TDM = therapeutic drug monitoring TKI = tyrosine kinase inhibitor UGT = uridine 5´-diphosphoglucuronosyltransferase VEGFR = vascular endothelial growth factor receptor Abstract: In advanced renal cell carcinoma, a transition of drug therapies from cytokines to molecular-targeted drugs and immune-oncology drugs provides more clinical benefits to patients, while adequate management is required for various and sometimes serious adverse events. At present, the relationship between the pharmacokinetics of many drugs and their effectiveness or adverse events has been elucidated, and therapeutic drug monitoring is being applied to some immunosuppressive, anti-epileptic and antibacterial drugs in daily clinical practice. Most of the molecular-targeted drugs used in patients with renal cell carcinoma are orally active, and are affected by absorption and disposition, which can be different for each individual. The monitoring of the circulating drug concentration could be beneficial to patients by providing information for the adjustment of drug dose and the maintenance of a therapeutic plasma concentration range. Genetic polymorphisms are known to be involved in pharmacokinetics, and cause individual differences in clinical efficacy and adverse events. Therefore, a more scientific strategy should be used in regard to the treatment of patients with advanced renal cell carcinoma treated with molecular-targeted drugs by accumulating evidence on pharmacodynamics and pharmacogenetics.
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Introduction
The transition of drug therapies from cytokines to molecular-targeted drugs and immuno-oncology drugs for advanced RCC provides more clinical benefits to patients, but adequate management is required for a variety of AEs that have never been encountered before. Although those AEs might be reversible and manageable by dose reduction or discontinuation, some AEs are irreversible, difficult to manage and life threatening. Significant research has so far been carried out in the field of PK, which describes how the drugs are absorbed, distributed, metabolized and excreted in the body, and PD, which describes how the drug positively or adversely affects the body. At present, TDM is being applied to some immunosuppressive, anti-epileptic and antibacterial drugs in daily clinical practice. In cancer treatment, the clinical application of PK and PD has been slow for several reasons. Combination chemotherapy with multiple agents has been the main modality of cancer treatment for many years, and sensitivity to each drug varies among different cancers and individuals. Alternatively, most molecular-targeted drugs are orally active, and are affected by absorption and disposition, which differ for each individual. Hence, the monitoring of the circulating drug concentration could be beneficial for cancer patients, because it can provide information for the adjustment of drug dose and the maintenance of a therapeutic plasma concentration range. Interest in pharmacogenetics has also emerged. Individual differences in various pharmacotherapies are regulated by genetic factors. The genetic polymorphisms involved in PK; that is, drug-metabolizing enzymes and membrane transporters, are thought to affect the circulating or organ drug concentration, thus resulting in differences in clinical efficacy and AE development. The present review article provides an overview of PK, PD, and pharmacogenetics of TKIs and mTOR inhibitors. Table 1 summarizes the association of pharmacokinetic parameters with response to the drugs, survivals and AEs. Table 2 summarizes the genetic polymorphisms related with the PK of each drug. The characteristics of each drug are discussed in detail in the following sections.
Tyrosine kinase inhibitors Sorafenib
Sorafenib is a multiple TKI that mainly targets rapidly accelerated fibrosarcoma kinases, VEGFRs and platelet-derived growth factor receptors. Sorafenib is oxidized by CYP3A4 to form the primary metabolite sorafenib N-oxide, which is glucuronidated by UGT1A9 and is mainly eliminated in the feces with a half-life of 20-48 h.
1,2 A significant interindividual variability has been seen in the PK of sorafenib. One Severe AE (C 0 >10 lg/mL) Fukudo et al. 7 
52
HT > G2 (C max >4.78 lg/mL) HFS > G2 (C max >5.78 lg/mL) Blanchet et al. 8 
22
AE G3 / C 0 Boudou-Rouquette et al. 9 
54
AE > G3 (AUC cum >3161 lg 9 h/mL) Sunitinib Houk et al.
146
Longer time to progression and OS (AUC 0-24 ≥800 ng 9 h/mL) Narjoz et al. 15 
55
Longer OS (total AUC 0-24 >1973 ng 9 h/mL) Noda et al. 16 
21
Shorter time to treatment failure and PFS (total C 0 ≥100 ng/mL) Bello et al. 12 
24
QT prolongation / C max , AUC, and C 0 Faivre et al. 13 
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Dose-limiting toxicity (sunitinib C 0 ≥100 ng/mL) Houk et al. 14 
146
HT / C 0 and absolute neutrophil count / AUC cum Noda et al. 16 
21
AE ≥G3 (total C 0 ≥100 ng/mL) Numakura et al. 18 
26
HFS and thrombocytopenia ≥G1 / sunitinib C 0 Mizuno et al. 19 
19
Thrombocytopenia ≥G2 (AUC 0-24 >2600 ng 9 h/mL) Axitinib Rini et al.
181
Univariate analysis: hazard ratio 0.558 for PFS, 0.489 for OS (AUC 0-12 ≥300 ng 9 h/mL) Multivariate analysis: hazard ratio 0.909 for PFS, 0.866 for OS (AUC 0-12 per 100 ng 9 h/mL increase) Rini et al. 35 
52
Longer OS, PFS, and higher overall response rate (cycle 1 day 1, 1-2 h concentration 45.2-56.4 ng/mL) Igarashi et al. 34 
46
Longer OS (AUC 0-12 ≥300 ng 9 h/mL and C 0 ≥5 ng/mL) Igarashi et al. 34 
HFS, hypothyroidism, proteinuria and anorexia ≥G2 (AE-specific cut-offs in AUC 0-12 and C 0 ) Kato et al. 36 
19
Dose discontinuation or reduction due to AEs (AUC 0-12 >97.3 ng 9 h/mL) Pazopanib Hurwitz et al. 44 
63
Best response (C 0 ≥15 lg/mL) Suttle et al. 45 
177
Longer PFS and tumor size reduction (C 0 >20.5 lg/mL) Verheijen et al. 69 
35
Longer PFS (C 0 >20 lg/mL) Hurwitz et al. 44 
63
HT >G3 and BP increase ≥15 mmHg (C 0 ≥15 lg/mL) Suttle et al. 45 
205
BP increase ≥15 mmHg / C 0 Everolimus Ravaud et al. 54 
178
Longer PFS (C 0 10-30 ng/mL vs <10 ng/mL) Thiery-Vuillemin et al. 55 
42
Longer FPS and OS (C 0 >14.1 ng/mL) Deppenweiler et al. 56 
†
Longer FPS (C 0 >11.9 ng/mL) Ferte et al. 57 
79
Oral ulcer / C 0 de Wit et al. 58 
40
Oral ulcer and dose reduction due to AEs / AUC Noguchi et al. 61 
1962
Pulmonary AEs (C 0 >30 ng/mL) Ravaud et al. 54 
938
≥G3 pulmonary AEs, stomatitis, and metabolic AEs / C 0 Shinsako et al. 62 
22
Termination of drug due to AEs / C 0 Deppenweiler et al. 56 
54
G3-4 toxicity (C 0 >26.3 ng/mL) †The study consists of 42 breast, 10 kidney and two neuroendocrine cancers. 
5
A allele of ABCG2 421A allele / higher AUC Diekstra et al. 70 
333
C allele of rs35599367 (CYP3A4), GG of rs776746 (CYP3A5), TT of rs2032582 (ABCB1), and CC of rs1128503 (ABCB1) / higher clearance Axitinib Brennan et al.
315
The closest to statistical significance in CYP2C19 genotype (PM) and the ABCB1 (G2677T/A) / AUC Igarashi et al. 34 
46
PM of UGT1A1 (*6/*6, *6/*28, or *28/*28) / plasma concentration Pazopanib Xu et al. 
16
NR1I2 rs6785049 / AUC sum and temsirolimus T 1/2 ABCB1 rs1128503 / sirolimus T 1/2 , AUC TOT , rs2032582 / sirolimus T 1/2 CYP3A5*3 (rs776746) / sirolimus C max report showed that the plasma concentration of sorafenib ranged from 881 to 12 526 ng/mL 2 weeks after the initiation of treatment with 400-600 mg b.i.d. 3 
PK and clinical efficacy
Few studies are available on the PD of sorafenib in patients with RCC. One study that included 94 patients with RCC treated with sorafenib showed that compliance and efficacy were improved in 16 patients with lower plasma concentration when the dose was increased to maintain the concentration above the average level. 3 However, that study did not precisely assess the association between plasma concentration and clinical efficacy. AEs might be present early in treatments with sorafenib and decrease over the course of the treatment; this finding was reported in a follow-up study of a phase III trial. 4 Another study investigated the change in PK over time in a real-world setting involving 15 patients with HCC. The study reported that the dose-normalized area under the plasma concentrationtime curve at day 30 (60.3 mg 9 h/L) decreased to 43.0 mg/ L h at day 90, followed by 33.2 mg 9 h/L with the disease progression. 5 A phase II trial that investigated the efficacy and safety of dose escalation in 41 patients with RCC who had progressive disease after a standard dose of sorafenib showed that 78% of the patients achieved stable disease. Tumor shrinkage was seen in 32 (19.5%) patients, and one (2.4%) patient had PR. The PFS was 7 months, which was comparable with previous studies. 6 Furthermore, 13 (32%) and 28 (68%) patients tolerated 800 and 600 mg b.i.d., respectively, thus suggesting that some patients received an insufficient therapeutic dose at PD, and that monitoring the plasma concentration of sorafenib is useful for selecting patients who benefit from dose escalation.
PK and AEs
A study investigated the PD of sorafenib in 16 patients with RCC and 36 patients with HCC. The results showed that the cut-offs for predicting grade ≥2 HFS and HT were 5.78 and 4.78 lg/mL, respectively. 7 Recently, Mai et al. showed the association of AEs and clinical efficacy with the plasma concentration of sorafenib in 94 patients with RCC. 3 The C ss at 2 weeks after the initiation of sorafenib administration with 400-1800 mg/day ranged from 881 to 12 526 ng/mL. The C ss of eight patients who suffered from severe AEs was >10 000 ng/mL. HFS, HT and alopecia were associated with higher C ss . For HCC, several studies showed that patients with AEs had higher plasma concentration or AUC of sorafenib than those without AEs. 8, 9 One study involving 52 patients with solid tumors, including six patients with RCC, reported that a cut-off AUC of 3161 lg 9 h/mL could predict the highest risk of developing grade ≥3 AEs. 9 Another study involving 25 patients with HCC reported that a higher plasma concentration of sorafenib N-oxide, a biologically active metabolite of sorafenib, was significantly associated with dose reduction or withdrawal at a cut-off of 2.0 lg 9 day/mL. 10 
Pharmacogenetics
Several studies have assessed the influence of genetic polymorphisms on the efficacy and toxicity of sorafenib. However, few studies have examined the direct effect of genetic polymorphisms on the PK of sorafenib. In a previous report that suggested the possible effect of the UGT1A1*28 haplotype on hyperbilirubinemia, a validation study was carried out of 120 patients with cancer. 11 The results showed that no association exists between UGT1A1 and UGT1A9 polymorphisms and sorafenib AUC. However, in patients with the UGT1A1*28 haplotype, ABCC2 À24C>T polymorphism could affect the AUC; that is, the C allele was associated with increased AUC.
Sunitinib
Sunitinib is demethylated by CYP3A4 to yield N-desethyl sunitinib (SU12662), which is suggested to have a biological activity. The half-life of sunitinib is 40-60 h, whereas that of SU12662 is 80-110 h, twofold longer than sunitinib. 12 The steady state of sunitinib can be reached 10-14 days after the initiation of each cycle. Furthermore, a phase 1 trial observed a wide interindividual variation of 30-150 ng/mL in the sunitinib C 0 at a dose of 50 mg q.d. 13 
PK and oncological efficacy
A meta-analysis of six studies investigated the association between PK/PD and clinical efficacy in 146 patients with metastatic RCC treated with sunitinib.
14 When patients were divided into two groups according to the total steady state AUC of sunitinib and SU12662 by using a cut-off value of 800 ng 9 h/mL, the higher AUC group had significantly prolonged time to progression and OS compared with the lower AUC group. This cut-off value of AUC was slightly less than the lower limit of therapeutic C 0 (50 ng/mL) previously reported in a phase I dose-finding trial. 13 One other study involving 55 patients with RCC reported that a higher AUC was associated with a significantly longer OS (35.2 months vs 16.7 months) and a tendency toward a longer PFS (35.2 months vs 8.4 months) than a lower AUC when using a cut-off of 1973 ng 9 h/mL, which was higher than the previous study. 15 
PK and AEs
A previous phase I study reported that the dose-limiting toxicity was associated with a total sunitinib C 0 of 100 ng/mL. 13 One study of 21 patients with RCC showed that a total sunitinib C 0 >100 ng/mL not only increased the incidence of toxicities of grade ≥3 (75.0% vs 23.1%), but also significantly shortened the time to treatment failure (71 days vs 590 days) and PFS (238 days vs 748 days) compared with a total sunitinib C 0 lower than the cut-off value. 16 A more recent study reported that TDM would have changed the sunitinib dose in 30% of the patients in the first cycle and in 46% of those over the whole treatment period by using an algorithm with a threshold AUC of 2150 ng 9 h/mL, which was found to be associated with the occurrence of grade ≥3 toxicity. 17 Other AEs including anorexia, fatigue, neutrocytopenia, thrombocytopenia, HFS, HT and QT prolongation have reportedly been associated with higher plasma concentration. 12, 14, 16, 18, 19 Considering all of these previous studies, the clinical benefit could be maximized by monitoring the sunitinib trough level and by adjusting the dose to be within 50-100 ng/mL of the therapeutic range, which corresponds to AUC 1200-2400 ng 9 h/mL.
Pharmacogenetics
Among the various genetic polymorphisms, ABCB1 and ABCG2 are being vigorously investigated in the PK of sunitinib. Both are membrane transporters that excrete compounds from within to outside the cells and harbor several important SNPs, which are thought to be involved in the interindividual variations in the PK of various drugs. In terms of ABCG2 C421A polymorphism, patients with allele A showed significantly higher AUC than those without allele A. 15, 19 There were some case reports in which patients with homozygotes of allele A of ABCG2 showed serious toxicity with exceedingly higher plasma concentrations of sunitinib. 20, 21 Meanwhile, it was reported that decreased clearance possibly resulting in higher plasma concentration was associated with CYP3A4*22, PM for CYP3A5 and ABCB1 SNPs. 22 Several studies described the clinical benefit of an alternative administration schedule, such as 2 weeks of treatment and 1 week off (2/1) instead of the standard 4 weeks of treatment and 2 weeks off (4/2) schedule. [23] [24] [25] According to the pharmacological data, both schedules were shown to have almost the same amount of time with C 0 in the therapeutic range. The 2/1 schedule could be beneficial for the patient to avoid increasing the severity of AEs and to ensure recovery from mild toxicity. 26 A more personalized dosing regimen is also advocated. 27 A personalized dose schedule can be designed by a simulation model using PK parameters and ABCG2 C421A genotype, such that the plasma concentration of sunitinib remains within the therapeutic range over the steady state.
Axitinib
Axitinib is pharmacologically characterized as a potent and highly selective inhibitor of VEGFRs 1, 2 and 3.
28 Axitinib is primarily metabolized by CYP3A and uridine diphosphate UGT1A1 to mainly form sulfoxide and glucuronide metabolites, which are considered biologically inactive. Its short half-life of 2.5-6.1 h is also an essential point, because it is greatly different from other TKIs. Physicians should be aware that plasma concentrations will often fluctuate because of the timing of the latest dose and the short half-life of axitinib. However, diet is considered to have minimal influence on plasma concentration. 29 The other important characteristic of axitinib is the ability to finely titrate the dose. In patients who tolerate an initial dose of 5 mg b.i.d., it might be titrated up to 10 mg b.i.d. under the close observation of BP and other toxicities. In a phase II study that tested the effectiveness of the dose titration of axitinib in 213 patients with metastatic RCC, the PR rate of the titration group was higher than the placebo group. 30 However, a recent study showed that dose titration has no survival advantage. 31 
PK and clinical efficacy
It is known that the plasma concentration of axitinib shows a very wide interindividual variation. A PK analysis in 17 clinical trials showed a significant interindividual variability in the AUC of axitinib at 4 weeks of treatment (before dose changes in most patients) with a range of 32.8-1728 ng 9 h/ mL. 32 Furthermore, the probability of achieving PR increased by every 100 ng 9 h/mL increase in AUC, and the higher AUC 0-12 group with a cut-off of 300 ng 9 h/mL had a significantly longer PFS (13.8 months vs 7.4 months) and OS (37.4 months vs 15.8 months) than the lower AUC 0-12 group. This cut-off of AUC corresponded to the estimated total daily exposure based on a previous study that showed the correlation with the maximum reduction in blood flow evaluated by dynamic contrast-enhanced magnetic resonance imaging. 33 Another study using an AUC of 300 ng 9 h/mL and a C 0 of 5 ng/mL as cut-offs at steady state showed that both cut-offs were significantly associated with OS (not reached vs 299 days and not reached vs 409 days, respectively) in 46 patients with RCC who did or did not have previous TKI therapy. 34 One study involving 52 patients with RCC compared the OS, PFS and overall response rate between four groups categorized by quartile values of 1-2 h post-dose plasma axitinib concentration on cycle 1 day 1. 35 As results, patients in quartile 3 (45.2-56.4 ng/mL) had a longer OS and PFS, and higher overall response rate than those in other quartiles (not estimable vs 20.3-27.7 months, 28.3 vs 7.5-11.8 months and 81.8% vs 16.7-53.8%, respectively).
PK and AEs
Although patients with excessive axitinib plasma concentration often encounter serious AEs, only a few studies evaluated the association between the PK of axitinib and AEs. An increased AUC 0-12 >97.3 ng 9 h/mL was reported to be associated with discontinuation or dose reduction due to AEs (77.8% vs 22.2%) in 20 patients with RCC. 36 One other study recently showed that AUC 0-12 or C 0 at steady state was significantly higher in patients with grade ≥2 AEs, HFS, hypothyroidism, proteinuria and anorexia. 34 The cut-off values of AUC 0-12 or C 0 vary among the types of AEs (250.9-422.2 ng 9 h/mL for AUC 0-12 and 6.6-7.1 ng/mL for C 0 ). However, severe AEs (grades 3 or 4) should be analyzed to identify the upper limit of the therapeutic range, which could be higher than reported.
BP has been identified as a biomarker of the plasma concentration of axitinib, and could possibly be used to predict a clinical response. In a phase II dose titration study, the titration group had a 10% higher incidence of both grades 1-2 (43%) and grade 3 (18%) HT than the placebo group (34% and 9%, respectively). 30 However, changes in diastolic BP from baseline had a weak correlation with AUC (R 2 = 0.225), and were not likely to be an ideal surrogate marker. 37 There was no significant difference in long-term PFS between the titration and placebo groups (14.5 months vs 15.7 months), 31 and in PFS between the quartile groups of AUC (11.5, 19.4, 13.9 and 13.7 months for the first, second, third and fourth quartiles, respectively), 37 thus suggesting that TDM over the treatment period should be given importance rather than a single measurement to achieve clinical benefit. A recent study showed the possible antitumor effect of the dose escalation of TKIs, such as axitinib, sunitinib and pazopanib, at the occurrence of progressive disease. 38 Among 18 patients with RCC who had progressive disease, 14 (78%) had a decrease in tumor burden, and the median duration of escalated therapy was 10.1 months. Although PK data were not available in that study, a dose escalation strategy might be beneficial to some patients with lower plasma TKI concentration in progressive disease.
Pharmacogenetics
A meta-analysis of 11 studies showed no association between the PK of axitinib and 15 drug-related genetic polymorphisms, with the closest statistical significance in the CYP2C19 genotype and in ABCB1 (G2677T/A). 39 One study involving 46 patients with RCC showed the association between the PM of UGT1A1 (*6/*6, *6/*28 or *28/*28), which was not analyzed in the previous meta-analysis, and high plasma concentration of axitinib, but the haplotypes were not related to treatment outcomes. 34 
Pazopanib
Pazopanib is another multikinase inhibitor that provides both therapeutic effect and favorable tolerability. 40, 41 It is metabolized mainly by CYP3A4, with CYP1A2 and CYP2C8 contributing to a smaller extent, to form its metabolites (M1-M7). 42 Only the M2 (GSK1268997) metabolite has a bioactivity similar to pazopanib. The other metabolites are reported to show a 10-to 20-fold lower activity than the parent compound. 43 The half-life of pazopanib is 31.1 h after a single dose of 800 mg q.d. 44 Pazopanib is a highly lipophilic compound, and is slightly soluble at pH 1 and insoluble above pH 4. 43 Therefore, the PK of pazopanib is likely to be affected by meals. More than a twofold increase of AUC 0-24 and C max has been reported in 19 patients with solid tumors who were given pazopanib after a high-fat meal compared with those given pazopanib in fasted status and then given a low-fat meal. 43 
PK and clinical efficacy
In a phase I trial, five of six patients with RCC with PR or stable disease achieved C 0 ≥15 lg/mL, but all four patients with progressive disease achieved C 0 <15 lg/mL. 44 A posthoc study using the PK/PD data of 205 patients with RCC in a phase II trial showed that the adequate cut-off C 0 of pazopanib was 20.5 lg/mL. 45 When this cut-off value was used, the high C 0 group showed a significantly longer PFS (52.0 weeks vs 19.6 weeks) and a significantly higher tumor shrinkage rate (37.9% vs 6.86%) than the lower C 0 group. 45 Another study retrospectively assessed the association between pazopanib C 0 and survival outcome in 35 patients with RCC, and reported that a C 0 >20 ng/mL was significantly related to longer PFS (34.1 weeks vs 12.5 weeks) than C 0 ≤20 ng/mL. One study introduced TDM to individualize the dose of pazopanib. 46 The dose was individualized from 200 to 1600 mg to keep the target AUC 0-24 in the range of 715 to 920 mg 9 h/L, which was defined on the basis of two previous phase I studies, 44, 47 during days 14-28 after treatment with a fixed dose of 800 mg q.d. However, they failed to show the feasibility of TDM in reducing interpatient variability. It is thought that the large intrapatient variability caused by meals and dose timing leads to negative results. Therefore, the standardization of blood sampling for PK is essential.
PK and AEs
A phase I trial showed that 20 (77%) of 26 patients with C 0 ≥15 lg/mL developed grade 3 HT, which is defined as a ≥15 mmHg increase from baseline, whereas just 11 (39%) of 28 patients with C 0 <15 ng/mL developed HT. 44 Similarly, a post-hoc analysis showed the relationship between C 0 and the occurrence of a significant increase in BP (≥15 mmHg). 45 
Pharmacogenetics
Thus far, there has been no report regarding the influence of genetic polymorphism on the PK of pazopanib. One study focused on pazopanib-induced hyperbilirubinemia and explored the associated genetic polymorphisms. 48 Liver toxicity is a common AE and often requires the discontinuation of the drug. 40, 49 Pazopanib is a potent inhibitor of UGT1A1, 48 which is the only enzyme involved in conjugating bilirubin and has polymorphisms known to affect the serum bilirubin concentration. 50 An exploratory analysis involving 116 patients with RCC in a phase I trial identified three candidate polymorphisms: TA-repeat, À3279T/G in UGT1A1 and À163C/A in CYP1A2. 51 Finally, a validation analysis in 130 patients from a phase III trial showed that the UGT1A1 TArepeat (T7/T7 and T7/T6) was significantly associated with the development of pazopanib-induced hyperbilirubinemia. 49 
mTOR inhibitors Everolimus
Everolimus is a mTOR kinase inhibitor, which forms a complex to bind everolimus/FKBP12 and inhibits mTORC1. mTORC1 consists of mTOR, regulatory-associated protein of mTOR and other components, thus leading to the phosphorylation of its downstream effector molecules (e.g. S6 and 4EBP1). Everolimus is mainly metabolized in the liver, primarily by CYP3A4, but also CYP3A5 and CYP2C8, to form four main metabolites. Its half-life is 30 h. 52 The effect of food on everolimus absorption was examined in 24 healthy individuals. 52 The study showed that a high-fat meal reduced C max and AUC by 60% and 16%, respectively, thus suggesting that a constant administration of everolimus either with or without food should be recommended during TDM.
PK and clinical efficacy
Everolimus as an immunosuppressant has a specific therapeutic range (3-8 ng/mL in combination with calcineurin inhibitors); therefore, dose adjustment by TDM is necessary after organ transplantation. Meanwhile, even though the standard dose of everolimus for cancer therapy is fivefold higher than that for immunosuppression therapy, just a few studies have assessed the association between PK and treatment outcome in patients with cancer. A phase I study recommended an oral dose of 10 mg/day because of the tolerability and strong inhibitions of pS6, peIF-4G, and peIF-4G expressions of tumor cells in patients treated with a dose of 10 mg/day compared with patients treated with a dose of 5 mg/day. 53 In the study, the mean C 0 values were 8.5 and 17.0 ng/mL, which correspond to 5 and 10 mg q.d., respectively. A pooled analysis consisting of 945 patients with various cancer types in five phase II/III trials showed that a twofold increase in everolimus C 0 increased the likelihood of tumor size reduction (odds ratio 1.40), and was associated with a tendency toward a reduced risk of progression (RR 0.90). 54 One study group also investigated the influence of everolimus C 0 on its activity in 42 patients with RCC. They showed that the median PFS and OS were longer in patients with C 0 >14.1 ng/mL than those with C 0 <14.1 ng/mL (13.3 months vs 3.9 months and 26.2 months vs 9.9 months, respectively); however, the difference was not statistically significant. 55 In another study of 54 patients with cancer, including 10 with RCC, the C 0 thresholds of 26.3 ng/mL for toxicity events and 11.9 ng/mL for cancer progression were proposed. 56 These target C 0 ranges, particularly the lower limit of C 0 , should be validated in studies with a larger number of patients with RCC.
PK and AEs
A study consisting of 41 patients with various cancer types from phase I and II trials showed that the median C 0 values in patients with and without oral ulcer were 12.86 and 4.60 ng/ mL, respectively. 57 Another study including 40 patients with thyroid cancer showed that patients with grade 3 stomatitis had a twofold higher mean AUC 0-24 (896 ng 9 h/mL vs 456 ng 9 h/mL) and C 0 (24.9 lg/L vs 10.3 lg/L) than those with grade 1 or lower stomatitis. It was also shown that patients who required dose reduction had a higher mean AUC 0-24 (600 ng 9 h/mL vs 395 ng 9 h/mL) and C 0 (14.9 ng/mL vs 8.4 ng/mL) than those who required no dose reduction. 58 Everolimus-induced pulmonary AEs, including pneumonitis and pulmonary fibrosis, occurred in 13-30% of patients, with a twofold higher incidence in Japanese patients than non-Japanese patients. 59, 60 A pooled analysis of 1962 patients in 32 studies whose C 0 data are available showed that C 0 >30 ng/mL was associated with the highest likelihood of any grade of pulmonary AEs, followed by C 0 10-30 ng/ mL. 61 Another pooled analysis showed that a twofold increase in C 0 significantly increased the risk of grade ≥3 pulmonary AEs (RR 1.93), stomatitis (RR 1.49) and metabolic AEs (RR 1.30). However, there was no association between C 0 and other grade ≥3 AEs including rash, bleeding, hematopoietic, infectious, renal and thrombocytopenic events. 54 In 22 patients with RCC, everolimus C 0 was not significantly different between patients with and without interstitial lung disease (20.6 ng/mL vs 20.0 ng/mL), thus suggesting that factors other than PK might be involved in the development of pulmonary AEs. 62 The same group showed no association between overall best responses and C 0 at day 8, but C 0 was significantly higher in patients who terminated everolimus owing to AEs than in patients who discontinued owing to progressive disease or other reasons (27.6 AE 3.1 ng/mL vs 15.7 AE 2.3 ng/mL, respectively). 63 Meanwhile, a divided dose of everolimus might improve its tolerability while maintaining therapeutic efficacy. A study consisting of 11 patients with cancer, including four patients with RCC, compared a 10 mg once-daily schedule with a 5 mg twice-daily schedule. It showed that a divided dose schedule reduced C max (61.5 ng/mL vs 40.3 ng/mL) without affecting C 0 (9.6 vs 13.7) or AUC (435 ng 9 h/mL vs 436 ng 9 h/mL). 64 Therefore, alternative dose scheduling might allow the effective and safe use of everolimus.
Pharmacogenetics
The effects of drug-related genetic polymorphism on the PK of everolimus have been assessed in 37 patients with breast cancer. 65 Among six polymorphisms in four genes (CYP3A4, CYP3A5, CYP2C8 and ABCB1), only a variant allele (T allele) of CYP3A4 rs35599367 (CYP3A4*22) was significantly associated with a 2.7-fold higher plasma concentration of everolimus than wild type (CC genotype; median of 69.1 ng/ mL vs 25.7 ng/mL, respectively).
Temsirolimus
Temsirolimus is a derivative and prodrug of sirolimus (rapamycin), and is clinically used intravenously. The intravenous administration of temsirolimus generally provides maximal bioavailability and enables the easy management of plasma concentration, thus resulting in better therapeutic response and decreased toxicity. Temsirolimus is metabolized in the liver primarily by CYP3A4 to form sirolimus, which is then predominantly excreted in feces. After the intravenous injection of temsirolimus, sirolimus is detected in the plasma in 15 min, with a peak of 30-120 min. 66 The half-life is 13 h for temsirolimus and 49 h for sirolimus at a dose of 25 mg/body. 67 As a consequence, sirolimus has a 2.5-to 3.5-fold higher AUC than temsirolimus, and achieves a detectable concentration of >10 ng/mL even when temsirolimus has almost disappeared from the blood after 7 days. 66 Furthermore, the study showed that dose adjustment based on body surface area did not minimize the interpatient variability in PK parameters. 66 A flat dose was then used in a further phase II trial.
Association of PK with clinical efficacy and AEs
In a phase II dose-finding trial in patients with advanced refractory RCC, a fixed weekly dose of temsirolimus of 25, 75 and 250 mg/body intravenous showed a dose-dependent, but non-linear, increase in C max and AUC with less interindividual variability in PK parameters than oral drugs; these three different dose groups showed similar PFS (6.3, 6.7 and 5.2 months, respectively) and OS (13.8, 11.0 and 17.5 months, respectively), and had an incidence of AE each. 67 However, drugrelated dose reduction and discontinuation rates were higher in the 75 (66%) and 250 mg (58%) groups than in the 25 mg (36%) group. As a result, 25 mg/body was used in further trials as a standard dose for patients with RCC.
Pharmacogenetics
Only one study has investigated the pharmacogenetics of temsirolimus, and the target of this study was patients with bladder cancer and not RCC. The study investigated the influence of seven SNPs in three genes, namely, CYP3A5, ABCB1 and NR1I2, on the PK parameters of temsirolimus in 16 patients with metastatic bladder cancer. 68 The NR1I2 rs6785049 GG genotype was associated with increased sirolimus plus temsirolimus AUC compared with other genotypes. Similarly, ABCB1 rs1128503 T allele and CYP3A5*3 haplotype were associated with higher sirolimus AUC and higher sirolimus C max , respectively. Given that this study only consisted of a small number of patients, the preliminary results should be confirmed in a larger number of patients.
Conclusions
The proposed strategy for drug therapy in patients with RCC is shown in Figure 1 . First, the optimal drug for each patient is selected using not only the pathological subtype, number of therapeutic lines or clinical risk classification, but also the tumor genomic profiling and polymorphisms of the cancer host, which predict the response to the drug and adverse effects. Second, the initial dose is determined by the polymorphisms of drug-related genes with the other clinical factors of each patient. Third, TDM is provided periodically to maintain the plasma concentration within the specified therapeutic range for each drug. When a patient encounters AEs, PK should be evaluated. If the plasma concentration is above the therapeutic range, the dose should be reduced to return the concentration to the therapeutic range. If the plasma concentration is within or below the therapeutic range, switching to other drugs should be considered. If a patient experiences progressive disease and if the plasma concentration is within or above the therapeutic range, it is mandatory to switch to other available drugs. If the plasma concentration is below the therapeutic range with tolerable AEs, dose escalation can be an option.
It has been >10 years since the first molecular-targeted drug became available for the treatment of advanced RCC with great expectations. Currently, more than half a dozen drugs are used routinely in daily practice. More recently, immuno-oncology drugs, such as immune check-point inhibitors, are partially taking the place of other drugs, and we are being inundated with information about novel drugs. In these circumstances, do we need to stop and think about whether we bring out the maximal efficacy of molecular-targeted drugs? Current practice involves empirical therapy through repeated trial and error with only a few clues of the clinical signs. It is clearly time to adopt a more scientific strategy for treatments using molecular-targeted drugs by accumulating evidence of PD and pharmacogenetics.
